Short Interest In Merrimack Pharmaceuticals Declines 12.8%

The most recent short interest data has been released by the NASDAQ for the 06/30/2014 settlement date, which shows a 2,672,732 share decrease in total short interest for Merrimack Pharmaceuticals Inc. ( MACK), to 18,222,633, a decrease of 12.79% since 06/13/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for MACK at the 06/30/2014 settlement increased to 2,641,757, as compared to 1,313,738 at the 06/13/2014 report. That brought "days to cover" down to 6.90, a 56.63% decrease from the 15.91 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for MACK at previous short interest release dates:

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

Loading+chart++2014+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where MACK had been shorted as a hedge.

The chart below shows the one year performance of MACK shares, versus its 200 day moving average. Looking at this chart, MACK's low point in its 52 week range is $2.05 per share, with $8.25 as the 52 week high point — that compares with a last trade of $6.79.

Merrimack Pharmaceuticals Inc. Chart

According to the ETF Finder at ETF Channel, MACK makes up 1.16% of the SPDR S&P Biotech ETF (XBI) which is higher by about 1% on the day Friday.

In afternoon trading Friday, MACK was down about 0.9% on the day.

If you liked this article you might like

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

Verastem Shares Are Exploding 50% -- Here's Why

Verastem Shares Are Exploding 50% -- Here's Why

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers